September 12, 2025

Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

Key Points

Datopotamab deruxtecan shows significantly lower IC50 in TROP2 expressing cell lines compared to control.
In cell lines with TROP2 expression, Dato-DXd exhibited lower IC50 values, with P < 0.05 for significance.
Control ADC displayed no significant difference in IC50 against the cell line with 0 TROP2 expression.
Cytotoxicity was evaluated using flow cytometry, establishing dose-response relationships for the drug.

Abstract

Flow cytometry–based cytotoxicity assay. Determination of Dato-DXd and control ADC IC50 (mean SEM) in the tested cell lines. A, Cell line with 0 TROP2 expression i.e., END(K)34 showed no difference in the IC50 of Dato-DXd and control ADC. B and C, Cell lines with high TROP2 expression 3+; i.e., END(K)254 and END(K)265 demonstrated significantly lower IC50 for Dato-DXd when compared with control ADC (P

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Niccolò G. Santin

Namrata Sethi

Stefania Bellone

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Actions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider